IEC Publishes IEC 62722:2026 for Herbal Extracts

On 15 May 2026, the International Electrotechnical Commission (IEC) released IEC 62722:2026, General Requirements for Quality Control and Active Ingredient Labelling of Herbal Extracts. This update introduces new mandatory testing requirements—including HPLC-MS/MS multi-target quantification, full-spectrum mycotoxin screening, and nanoscale particle size distribution analysis—and has been adopted as an import准入 basis by Singapore’s Health Sciences Authority (HSA) and the UAE’s Ministry of Health and Prevention (MOHAP). Exporters and testing service providers in China report a 40% reduction in certification cycle time—from 18 to 10.5 days—following alignment by major labs including SGS China and CTI Certification. Companies engaged in herbal extract trade, formulation, or regulatory compliance should monitor implications for export efficiency, testing scope, and market access strategy.

Event Overview

The International Electrotechnical Commission (IEC) officially published IEC 62722:2026 on 15 May 2026. The standard specifies general requirements for quality control and active ingredient labelling of herbal extracts. It newly mandates three analytical methods: high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) for multi-target quantitative analysis; comprehensive mycotoxin profiling; and nanoscale particle size distribution testing. Singapore’s Health Sciences Authority (HSA) and the United Arab Emirates’ Ministry of Health and Prevention (MOHAP) have formally recognized the standard as a basis for import clearance. In China, leading third-party testing organizations—including SGS China and CTI Certification—have launched expedited certification pathways, reducing average turnaround time from 18 days to 10.5 days.

Impact on Specific Industry Segments

Direct Exporters
Exporters of herbal extracts face revised technical documentation and test reporting expectations. Compliance now requires evidence of all three newly mandated analyses—not just presence/absence results but validated quantitative data across multiple analytes and physical parameters. This affects pre-shipment planning, certificate-of-analysis formatting, and communication with overseas importers who rely on IEC 62722:2026 for customs clearance.

Raw Material Sourcing Firms
Firms procuring botanical raw materials must now verify supplier capacity to support downstream IEC 62722:2026 testing. Since mycotoxin screening and particle size distribution are highly dependent on upstream processing (e.g., drying method, milling precision), sourcing decisions increasingly require traceability to processing conditions—not only species and origin.

Extraction & Formulation Manufacturers
Manufacturers performing extraction, concentration, or nano-formulation must ensure process consistency supports reproducible HPLC-MS/MS quantitation and narrow particle size distributions. Batch-to-batch variability that previously fell within internal specifications may now fail against the tighter analytical thresholds implied by standardized multi-target quantification and nanoscale metrology.

Distribution & Regulatory Support Providers
Logistics and regulatory consultancies serving herbal extract exporters must update their compliance checklists and client advisories to reflect the three new mandatory tests. Documentation packages now require certified reports from IEC 62722:2026-aligned labs—not generic ISO/IEC 17025 certificates—and must explicitly reference test parameters (e.g., number of mycotoxins screened, Dv50/Dv90 values).

Key Considerations for Affected Enterprises and Practitioners

Monitor official adoption timelines beyond initial announcements

While Singapore HSA and UAE MOHAP have announced recognition of IEC 62722:2026, formal implementation dates, transitional arrangements, and enforcement protocols remain pending. Enterprises should track updates directly from these authorities—not rely solely on press releases or industry summaries.

Verify test scope alignment with target markets—not just lab accreditation

Not all IEC 62722:2026-aligned labs perform identical mycotoxin panels or particle size measurement protocols. Exporters must confirm that their chosen lab’s test report meets the specific analyte list and reporting format required by HSA or MOHAP—particularly for mycotoxin coverage (e.g., whether enniatins or beauvericin are included) and particle size descriptors (e.g., volume-weighted vs. number-weighted distributions).

Assess supply chain readiness for multi-target quantification

HPLC-MS/MS multi-target quantification requires reference standards, validated methods, and instrument calibration for each active compound. Suppliers lacking infrastructure for this level of analytical rigor may delay certification. Exporters should audit current suppliers’ testing capabilities—or identify alternative labs capable of delivering compliant reports within the 10.5-day window.

Update internal quality documentation before shipment cycles begin

Certificates of Analysis must now include explicit statements confirming conformance to IEC 62722:2026, along with full method descriptions and uncertainty statements for each mandatory test. Preparing templates and training QA staff on these new reporting requirements ahead of first shipments avoids last-minute delays.

Editorial Perspective / Industry Observation

Observably, IEC 62722:2026 functions less as a standalone technical document and more as a harmonization signal across regulatory jurisdictions. Its adoption by HSA and MOHAP—two agencies with distinct historical approaches to botanical product regulation—suggests convergence toward standardized, instrumentation-driven verification rather than country-specific interpretation. Analysis shows this reflects a broader shift: regulators increasingly treat herbal extracts not as traditional commodities but as analytically defined functional ingredients. That said, the standard’s immediate impact remains constrained to markets that have formally referenced it; its influence on EU, US, or Japanese import rules is not yet evident and should not be assumed. Current relevance is strongest for exporters targeting Singapore and the UAE—and for service providers supporting those flows.

Conclusion
IEC 62722:2026 marks a step toward greater analytical rigor and cross-border harmonization for herbal extract trade—but its operational significance is currently limited to specific regulatory adoptions and corresponding certification pathways. It is better understood as an early-stage alignment mechanism rather than a globally binding requirement. Enterprises should treat it as a near-term compliance priority for targeted markets, not a universal benchmark. Ongoing monitoring of implementation details—not just the standard’s existence—is essential for accurate risk assessment and planning.

Information Sources
Primary source: International Electrotechnical Commission (IEC), IEC 62722:2026 publication notice (15 May 2026).
Regulatory references: Singapore Health Sciences Authority (HSA) public statement; UAE Ministry of Health and Prevention (MOHAP) circular.
Testing service confirmation: Public announcements from SGS China and CTI Certification regarding expedited IEC 62722:2026 certification pathways.
Note: Implementation timelines, enforcement guidance, and potential future adoptions by other jurisdictions remain under observation and are not confirmed at time of publication.